Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq and RNA-seq in breast cancer cell lines

ABSTRACT: ChIP-seq and RNA-seq in breast cancer cell lines

PROVIDER: PRJNA802218 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17832100_1.fastq.gz	Fastqsanger.gz
	SRR17832100_2.fastq.gz	Fastqsanger.gz
	SRR17832079_1.fastq.gz	Fastqsanger.gz
	SRR17832079_2.fastq.gz	Fastqsanger.gz
	SRR17832080_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

ChIP-seq of EYA2 in breast cancer cell lines

Project description:ChIP-seq of EYA2 in breast cancer cell lines

| PRJNA656256 | ENA

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha

Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

ChIP-seq of EYA2 in breast cancer cell lines

Project description:ChIP-seq of EYA2 in breast cancer cell lines

2022-03-22 | GSE155977 | GEO

EBF1 and HIF1a ChIPseq in breast cancer cell lines [ChIP-seq]

Project description:EBF1 and HIF1a ChIPseq in breast cancer cell lines [ChIP-seq]

| PRJNA802116 | ENA

Genome-wide maps of XBP1 binding sites in different breast cancer cell lines [ChIP-Seq]

Project description:We report the application of ChIP-seq, which combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing, to map genome-wide XBP1 binding sites in different breast cancer cell lines. We showed that HIF1M-NM-1 motif was enriched in XBP1 binding sites in triple negative breast cancer (TNBC) cell lines, but not enriched in ER positive breast cancer cell line. We also demonstrated that different breast cancer cell lines of the same sub-type had similar XBP1 binding sites, whereas different breast cancer sub-types had majorly different XBP1 binding sites. Finally, a model was applied to integrate XBP1 ChIP-seq data with expression data to predict XBP1's direct targets in TNBC cell line; the predicted direct targets were shown to be predictive of patient survival, and the prediction power was specific to TNBC patients. The above evidence indicates that XBP1 performs important functions in TNBC by interacting with HIF1M-NM-1, and such regulation mechanism is specific to TNBC, which is later proved by follow-up experiments.This study represents the first detailed anaysis of XBP1 binding sites in different breast cancer cell lines. Examination of XBP1 binding sites in 2 cell types (3 cell lines).

2013-09-26 | E-GEOD-49952 | biostudies-arrayexpress

ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib

| PRJNA547761 | ENA

ChIP-seq for FOXA1, ER and CTCF in breast cancer cell lines

Project description:ChIP-seq for FOXA1, ER and CTCF in breast cancer cell lines

| PRJEB2316 | ENA

ATAC-seq, ChIP-seq and RNA-seq of breast cancer cell lines post ligand treatment

Project description:ATAC-seq, ChIP-seq and RNA-seq of breast cancer cell lines post ligand treatment

| PRJNA483771 | ENA

Genome-wide maps of XBP1 binding sites in different breast cancer cell lines [ChIP-Seq]

Project description:We report the application of ChIP-seq, which combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing, to map genome-wide XBP1 binding sites in different breast cancer cell lines. We showed that HIF1α motif was enriched in XBP1 binding sites in triple negative breast cancer (TNBC) cell lines, but not enriched in ER positive breast cancer cell line. We also demonstrated that different breast cancer cell lines of the same sub-type had similar XBP1 binding sites, whereas different breast cancer sub-types had majorly different XBP1 binding sites. Finally, a model was applied to integrate XBP1 ChIP-seq data with expression data to predict XBP1's direct targets in TNBC cell line; the predicted direct targets were shown to be predictive of patient survival, and the prediction power was specific to TNBC patients. The above evidence indicates that XBP1 performs important functions in TNBC by interacting with HIF1α, and such regulation mechanism is specific to TNBC, which is later proved by follow-up experiments.This study represents the first detailed anaysis of XBP1 binding sites in different breast cancer cell lines.

2013-09-26 | GSE49952 | GEO

ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib [H3K9me3]

Project description:ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib [H3K9me3]

| PRJNA548957 | ENA